About Nervosave Therapeutics

Nervosave Therapeutics develops local gene therapies using AAV9 vectors to target peripheral nerve diseases, specifically focusing on Charcot-Marie-Tooth (CMT) disease types 1A and 4. Their platform aims to slow, stop, and potentially reverse the progression of debilitating conditions such as neuralgias and diabetic peripheral neuropathy.

```xml <problem> Peripheral nerve diseases, such as Charcot-Marie-Tooth (CMT) disease, neuralgias, and diabetic peripheral neuropathy, lead to debilitating conditions with limited effective treatments. Current therapeutic options often fail to address the underlying causes of nerve degeneration, resulting in progressive loss of function and reduced quality of life. The lack of targeted therapies leaves a significant unmet need for patients suffering from these conditions. </problem> <solution> Nervosave Therapeutics is developing local gene therapies utilizing adeno-associated virus (AAV9) vectors to target the underlying causes of peripheral nerve diseases. Their platform aims to deliver therapeutic genes directly to affected nerve cells, with the goal of slowing, stopping, and potentially reversing disease progression. By focusing on local delivery, Nervosave seeks to minimize systemic exposure and maximize therapeutic efficacy in specific nerve tissues. The initial focus is on Charcot-Marie-Tooth (CMT) disease type 1A, with plans to expand the platform to address other CMT subtypes and nerve-related conditions. </solution> <features> - AAV9-based gene therapy vectors for targeted delivery to peripheral nerve cells - Local administration to minimize systemic effects and maximize therapeutic concentration at the site of nerve damage - Focus on Charcot-Marie-Tooth (CMT) disease type 1A as the lead indication - Potential application to a range of peripheral nerve diseases, including neuralgias and diabetic peripheral neuropathy </features> <target_audience> The primary target audience includes patients diagnosed with Charcot-Marie-Tooth (CMT) disease and other peripheral nerve disorders, as well as the physicians and specialists who treat these conditions. </target_audience> ```

What does Nervosave Therapeutics do?

When was Nervosave Therapeutics founded?

Nervosave Therapeutics was founded in 2021.

Founded

2021

Employees

4 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Nervosave Therapeutics

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

nervosavetx.com 500+

Founded 2021

Funding

No funding information available.

Team (<5)

No team information available.

Company Description

Problem

Peripheral nerve diseases, such as Charcot-Marie-Tooth (CMT) disease, neuralgias, and diabetic peripheral neuropathy, lead to debilitating conditions with limited effective treatments. Current therapeutic options often fail to address the underlying causes of nerve degeneration, resulting in progressive loss of function and reduced quality of life. The lack of targeted therapies leaves a significant unmet need for patients suffering from these conditions.

Solution

Nervosave Therapeutics is developing local gene therapies utilizing adeno-associated virus (AAV9) vectors to target the underlying causes of peripheral nerve diseases. Their platform aims to deliver therapeutic genes directly to affected nerve cells, with the goal of slowing, stopping, and potentially reversing disease progression. By focusing on local delivery, Nervosave seeks to minimize systemic exposure and maximize therapeutic efficacy in specific nerve tissues. The initial focus is on Charcot-Marie-Tooth (CMT) disease type 1A, with plans to expand the platform to address other CMT subtypes and nerve-related conditions.

Features

AAV9-based gene therapy vectors for targeted delivery to peripheral nerve cells

Local administration to minimize systemic effects and maximize therapeutic concentration at the site of nerve damage

Focus on Charcot-Marie-Tooth (CMT) disease type 1A as the lead indication

Potential application to a range of peripheral nerve diseases, including neuralgias and diabetic peripheral neuropathy

Target Audience

The primary target audience includes patients diagnosed with Charcot-Marie-Tooth (CMT) disease and other peripheral nerve disorders, as well as the physicians and specialists who treat these conditions.